Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has granted three new US patents, further strengthening Mersana Therapeutics' intellectual property (IP) position in next-generation antibody-drug conjugate (ADC) technologies that use the Fleximer polymer.
Subscribe to our email newsletter
The US patent no. 8,808,679 provides coverage for anti-tumor payloads and customized linkers used in the company’s Dolaflexin conjugation platform.
The second US patent no. 8,815,226 expands its IP portfolio to include Fleximer platform technology that is optimized to create ADCs with antibody alternatives.
The third patent 8,821,850, offers broad coverage for Fleximer-based ADCs and use thereof.
Together with US patent no. 8,685,383, which issued earlier in 2014, the claims of these patents provide the company with expansive IP protection for its new, highly differentiated platform technologies.
Mersana Therapeutics chief business officer Eva Jack said the company’s strong intellectual property position provides a comprehensive ADC solution for its internal pipeline as well as its partners’ programs by covering proprietary payloads, Fleximer polymer linker technology, and conjugation to antibodies or antibody alternatives.
"Our ability to create ADCs with full length antibodies and a variety of antibody alternatives, payloads, and linkers, demonstrates our technology’s inherent flexibility and our leading position among companies with next-generation ADC technologies," Jack said.
"We are committed to the ongoing advancement of Fleximer-based ADCs to address unmet needs and improve patient outcomes."
The next-generation Fleximer ADC technology is based on the company’s biodegradable polymer system, known as Fleximer, and a wide variety of linkers that allow for the attachment of an extensive range of anti-tumor payloads to Fleximer.